Castle Biosciences Profit Margin

The latest profit margin for CSTL is -5.43% as of June 2026. That compares with -2.73% in the prior-year period — down 98.8% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Castle Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSTL's profit margin moved from -2.73% to -5.43% — a 98.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Castle Biosciences's valuation or profitability profile.

Against Healthcare companies, CSTL currently prints -5.43% for profit margin, while the sector average sits near 15.29%. That is roughly 135.5% below the sector mean. Large gaps often invite a closer look at Castle Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Castle Biosciences converts resources into returns. At -5.43%, CSTL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2.73% in the prior-year period — down 98.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CSTL's profit margin (-5.43%), review year-over-year change from -2.73%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.